Relationship between Patients’ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 4

Differences in overall survival associated with immunotherapy in ECOG PS by subgroups.

		Participants, no.		Pooled HR (95% CI) for ICI vs. controlled therapies		Test for difference
Variable	Studies, no.	ECOG 0		ECOG 0		value
Overall	18	4853	8414	0.77 (0.71, 0.84)	0.76 (0.70, 0.82)	0.765
Line of therapy
First	11	3014	5165	0.76 (0.67, 0.87)	0.78 (0.71, 0.86)	0.768
Subsequent	7	1839	3249	0.79 (0.70, 0.89)	0.73 (0.63, 0.85)	0.432
Intervention therapy
ICI alone	11	2723	5102	0.76 (0.69, 0.84)	0.76 (0.68, 0.85)	0.993
ICI combined with non-ICI	7	2130	3312	0.79 (0.67, 0.93)	0.78 (0.70, 0.88)	0.977
Pathologic types
Squamous	4	711	1543	0.79 (0.58, 1.09)	0.73 (0.65, 0.89)	0.66
Nonsquamous	5	1662	2377	0.72 (0.61, 0.86)	0.78 (0.67, 0.90)	0.513

Abbreviations: HR = hazard ratio; ICI = immune checkpoint inhibitor.